istock-485508035-alexandrumagurean

alexandrumagurean / iStockphoto.com

13 September 2018Big Pharma

LSIPR webinar: HGF delves into personalised healthcare patents

Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

More on this story

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

More on this story

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

More features

'Nothing can stand in the way of our work': Ukraine resumes IP system

Life sciences leaders recognised at LSPN Awards USA 2025

LSPN: Trump's policy storm causing chaos and confusion

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Foley adds five-partner team from Perkins Coie and K&L Gates

UPC orders 17-country ban on EOFlow's pumps in Insulet feud